Icon (NASDAQ:ICLR) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday.

Several other brokerages have also recently commented on ICLR. Goldman Sachs Group cut shares of Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 price target on the stock. in a research note on Friday, December 14th. Barclays boosted their target price on shares of Icon from $130.00 to $140.00 and gave the stock an “equal weight” rating in a report on Thursday, February 21st. Mizuho upgraded shares of Icon from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $146.00 to $150.00 in a report on Friday, January 25th. Zacks Investment Research upgraded shares of Icon from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. Finally, SunTrust Banks restated a “buy” rating and issued a $161.00 target price on shares of Icon in a report on Monday, February 25th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Icon presently has an average rating of “Hold” and a consensus target price of $152.60.

Shares of ICLR stock opened at $134.64 on Friday. The firm has a market capitalization of $7.11 billion, a price-to-earnings ratio of 21.41, a P/E/G ratio of 1.65 and a beta of 0.66. Icon has a 52 week low of $110.21 and a 52 week high of $155.33. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.18 and a current ratio of 2.18.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 20th. The medical research company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.60 by $0.02. The business had revenue of $679.03 million for the quarter, compared to analysts’ expectations of $675.04 million. Icon had a net margin of 12.43% and a return on equity of 26.01%. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.43 EPS. As a group, equities analysts expect that Icon will post 6.82 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC grew its holdings in Icon by 4.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 2,197 shares of the medical research company’s stock valued at $283,000 after purchasing an additional 101 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in Icon by 36.6% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 116 shares during the last quarter. CWM LLC grew its holdings in Icon by 211.8% during the 4th quarter. CWM LLC now owns 212 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 144 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Icon by 10.0% during the 4th quarter. Mackenzie Financial Corp now owns 1,897 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 173 shares during the last quarter. Finally, Rehmann Capital Advisory Group grew its holdings in Icon by 75.5% during the 3rd quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 179 shares during the last quarter. Hedge funds and other institutional investors own 86.41% of the company’s stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: What is a bull market?

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.